Dumin Overdose

Did you have any side effects with this medicine?
sponsored

What happens if I overdose Dumin?

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include fast or irregular heartbeat; inability to urinate; nausea; severe headache; vomiting.

Proper storage of Dumin:

Dumin is usually handled and stored by a health care provider. If you are using Dumin at home, store Dumin as directed by your pharmacist or health care provider.

Overdose of Dumin in details

When a dose is taken in higher dose than the recommended doses, it is called Overdose. Overdose always needs a clinical supervision. Any medicine or drug when consumed in Overdose produces untoward side effects on one or various organs in the body. A medicine is excreted in the kidney or metabolized in the liver most of the times. This process goes without any hurdles when taken in normal dose, but when taken in an overdose, the body is not able to metabolize it or send it out properly which causes the effects of anoverdose.
sponsored

In case of accidental overdosage, as evidenced by excessive blood pressure elevation, reduce rate of administration or temporarily discontinue Dumin until patients condition stabilizes. Since the duration of action of Dumin is quite short, no additional remedial measures are usually necessary. If these measures fail to stabilize the patients condition, use of the short acting alpha adrenergic blocking agent, phentolamine, should be considered.

What should I avoid while taking Dumin?

Follow your doctor's instructions about any restrictions on food, beverages, or activity.

Dumin warnings

Warnings are a mix of Precautions. Contraindications and interactions and serious harmful effects associated with the medicine intake. A diabetic or Hypertensive patient need to be warned about few drug interactions. A known hypersensitivity patient needs to be careful about the reactions or anaphylactic shock. A pregnant woman or a breastfeeding woman should be warned of certain medications. A Hepatitis [liver disease] patient or a cardiac patient should avoid few drugs.

Do not add any alkalinizing substance since Dumin is inactivated in alkaline solution.

Patients who have been treated with monoamine oxidase (MAO) inhibitors prior to the administration of Dumin will require substantially reduced dosage. See Drug Interactions below.

This product contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is: seen more frequently in asthmatic than in nonasthmatic people.

Evidence is inadequate for fully defining proper dosage and limitation for use in children.

Solutions containing dextrose without electrolytes should not be administered simultaneously with blood through the same infusion set because of the possibility of agglomeration of erythrocytes.

The administration of intravenous solutions can cause fluid and/or solute overload resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema.

Excess administration of potassium-free solutions may result in significant hypokalemia.

Because dosages of this drug are titrated to response, no additives should be mixed with Dumin Hydrochloride in 5% Dextrose Injection USP.

What should I discuss with my healthcare provider before taking Dumin?

Some medical conditions may interact with Dumin. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

Some MEDICINES MAY INTERACT with Dumin. Tell your health care provider if you are taking any other medicines, especially any of the following:

This may not be a complete list of all interactions that may occur. Ask your health care provider if Dumin may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

Dumin precautions

Certain people who are very sick or very old or who are sensitive show an exacerbation of side effect of the drug which can turn dangerous at times. So, it is very important to remember the precautions while taking the medicine. Pregnancy and Breastfeeding are also special categories wherein extra care or precaution is needed when taking a drug. Few patients may have a hypersensitivity reaction to few medications, and that can be life-threatening rarely. Penicillin hypersensitivity is one example. Diarrhea, rashes are few other symptoms which need a watch. A patient with other co-existing diseases like liver disease, heart disease, kidney disease should take special precautions.
sponsored

Patients who are taking MAOIs or who have taken them within the last 2-3 weeks require a substantially reduced starting dose ie, about 1/10 the usual dose.

Dumin should not be added to alkaline diluents.

Hypovolemia should be fully corrected prior to treatment with Dumin with a suitable plasma expander or whole blood or plasma until the central venous pressure is 10-15 cm H2O or the pulmonary wedge pressure is 14-18 mmHg.

Excessive dosage may be indicated by a disproportionate rise in diastolic pressure (ie, a marked decrease in pulse pressure). The infusion rate should be decreased or ceased.

Those patients with preexisting peripheral vascular disease eg, that due to artherosclerosis, arterial embolism, Buerger's disease, Raynaud's disease, diabetic endarteritis or cold injury (eg, Frostbite), may be more susceptible to peripheral ischemia and subsequent gangrene and should be observed carefully for any changes in color or temperature of the skin in extremities. If ischemia occurs and is thought to be due to vasoconstriction, the benefits of Dumin infusion should be weighed against the risks of possible necrosis. Ischemia may be reversed by either decreasing the rate or discontinuing the infusion.

Intravenous administration of phenatolamine 5-10 mg may also reverse the ischemia.

As with any cardiac stimulant, care should be exercised when administering Dumin to patients with cardiac ischemia.

Acidosis, hypercapnia or hypoxia may reduce the effectiveness and/or increase the incidence of adverse effects of Dumin. These conditions should be corrected prior to or concurrently with administration of Dumin.

Pulmonary hypertension may be exacerbated due to Dumin-induced pulmonary vasoconstriction. Where Dumin-induced pulmonary hypertension has occurred, isoprenaline may be considered as an alternative inotropic agent.

Routine monitoring of blood pressure, ECG, cardiac status and renal output, is necessary in all patients. Where possible, the cardiac output and pulmonary wedge pressure should be measured.

If a disproportionate rise in the diastolic pressure (ie, a marked decrease in the pulse pressure) is observed, the infusion rate should be decreased or suspended and the patient observed closely, unless such an effect is required.

Sterile Dumin concentrate contains sodium metabisulfite, which may cause allergic-type reactions, including anaphylactic symptoms and the life-threatening or less severe asthmatic episodes in susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than non-asthmatic people.

Hypotension may occur when attempting to wean patients from Dumin and it may be neccessary to substitute Dumin with another pressor agent or to expand blood volume whilst gradually reducing the infusion rate.

Dumin should be infused into a large vein whenever possible to prevent the possibility of extravasation into tissue adjacent to the infusion site. The infusion site should be continuously monitored for free flow

Carcinogenicity, Genotoxicity & Impairment of Fertility: The genotoxic potential of Dumin has not been evaluated. Long-term studies in animals have not been performed to evaluate the carcinogenic potential of Dumin. Studies in animals have not been performed to assess the effects of Dumin on fertility.

Use in pregnancy: Category B3. Drug which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have shown evidence of increased fetal damage, the significance of which is considered uncertain in humans.

It is not known whether Dumin crosses the placental barrier. In 1 animal study, the administration of Dumin to pregnant rats resulted in a decreased survival rate of the newborn and cataract formation in the survivors. The benefits of using this product should be weighed against the possible risks to the fetus.

Use in lactation: It is not known whether Dumin is excreted in breast milk, nor is the effect on the infant known. Dumin is inactive when ingested orally, nonetheless, it is not recommended for breastfeeding mothers unless the expected benefits outweigh any potential risks.

Use in children: It is not recommended for use in children as safety and efficacy in this age group has not been established.

What happens if I miss a dose of Dumin?

When you miss a dose, you should take it as soon as you remember, but you should take care that it should be well spaced from the next dose. You should not take an extra dose at the time of the second dose as it will become a double dose. The double dose can give unwanted side effects, so be careful. In chronic conditions or when you have a serious health issue, if you miss a dose, you should inform your health care provider and ask his suggestion.

Since Dumin injection is given by a healthcare professional in a medical setting, you are not likely to miss a dose.


sponsored

References

  1. DrugBank. "dopamine". http://www.drugbank.ca/drugs/DB00988 (accessed September 17, 2018).
  2. MeSH. "Sympathomimetics". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).

Reviews

Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 30 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2022 ndrugs.com All Rights Reserved